Cronos Group Inc is primarily active in the cannabis industry.

The main competitors of Cronos Group Inc in the market are Canopy Growth Corporation, Aurora Cannabis Inc, and Tilray Inc.

Cronos Group Inc, a leading Canadian cannabis company, has a rich history and background. Founded in 2013, it quickly established itself as a pioneer in the cannabis industry. The company operates globally and focuses on developing and distributing high-quality cannabis products. Cronos Group Inc has successfully formed partnerships with renowned brands, such as Marlboro-maker Altria Group, enhancing its market position. With a commitment to innovation and sustainability, Cronos prides itself on its diverse portfolio of brands and a strong research and development team. As a market leader, Cronos Group Inc continues to shape the future of the cannabis industry with its dedication to excellence and commitment to delivering shareholder value.

Cronos Group Inc has achieved several significant milestones. The company became the first cannabis producer to be listed on a major stock exchange in 2018, trading on the NASDAQ under the ticker symbol CRON. Additionally, Cronos Group Inc expanded its global presence by entering strategic partnerships and acquisitions in various countries. These include a joint venture in Israel, a supply and distribution agreement in Germany, and a partnership in Australia. Furthermore, the company has focused on research and development initiatives to innovate and develop novel cannabinoid-based products. Cronos Group Inc continues to make strides in the cannabis industry, positioning itself for further growth and success.

Cronos Group Inc is primarily present in Canada and the United States.

Cronos Group Inc represents core values of integrity, innovation, and responsibility. As a leading global cannabinoid company, Cronos Group is committed to providing innovative and high-quality products to its customers. The company's corporate philosophy revolves around transparency, sustainability, and community partnerships. Cronos Group focuses on advancing cannabinoid research, developing industry-leading intellectual property, and driving the growth of the cannabis industry. With a commitment to regulatory compliance and ethical practices, Cronos Group Inc prioritizes the well-being and satisfaction of their stakeholders while promoting the benefits of cannabinoid-based therapies.

Analysts currently set an average price target of 3,36 USD for the Cronos Group stock (median: 3,36 USD), implying +22,8 % versus the latest price. The consensus is based on 8 analyst ratings.

Cronos Group Analyytikkojen kursstavoitteet 2026

9 analysts currently rate the Cronos Group stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Cronos Group to generate revenue of 194,87 M USD and earnings per share of 0,09 USD.

Cronos Group Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Cronos Group share trades at 2,37 EUR (2,74 USD).

The Cronos Group share (CRON.TO) is listed on 5 stock exchanges, including: NASDAQ (CRON), Frankfurt (7CI.F), München (7CI.MU), Düsseldorf (7CI.DU), Toronto (CRON.TO).

The Cronos Group Inc is a Canadian company that operates in the manufacturing and marketing of cannabis products. Cronos' business model is based on vertical integration, allowing the company to complete all steps from cultivation to sales under one roof. One of Cronos' core divisions is cannabis cultivation. The company operates its own cultivation areas in Canada and other countries, equipped with the latest technology and highest standards. Through outdoor and indoor cultivation, Cronos can offer a wide range of cannabis varieties that cater to individual customer needs. Another important aspect of Cronos is the production of cannabis extracts and derivatives. The company utilizes its own cultivation areas and processes the harvested material into high-quality products such as oils, tinctures, capsules, and vapes. The broad portfolio of cannabis derivatives allows Cronos to target different market segments and cover a wide range of applications. In addition to production, Cronos also offers comprehensive consulting services. Experienced consultants and experts are available to assist customers in selecting the right product and individual dosage. This builds trust and customer satisfaction and strengthens the company's image as a responsible cannabis provider. Cronos markets its products through various channels, including its own online shop, retailers, and wholesalers. The company has been particularly successful in international marketing. Cronos collaborates with partners in different countries to position its products in the global market. The company focuses on a high-quality brand strategy and clear positioning as a premium provider. In addition to the mentioned business areas, Cronos also invests in research and development. This is aimed at strengthening the company's position as an innovation leader in the cannabis industry and exploring new applications. One focus is on the medical use of cannabis derivatives, which have shown positive effects in numerous medical conditions. Overall, Cronos' business model is characterized by a clear strategy, professional management, and a broad portfolio of high-quality products. Successful international marketing and positioning as a premium provider contribute significantly to the company's success. Investments in research and development will continue to support Cronos in offering innovative products and expanding its market position.

odotettu liikevaihto Cronos Group on 194,87 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Cronos Group on 34,79 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Cronos Group:n hinta-voitto-suhde (P/E) on tällä hetkellä 30,20. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Cronos Group-osakkeen arvostusta.

Cronos Group:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,39. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Cronos Group-osakkeen arvostuskennuslukuna.

Cronos Group:n Eulpool-laatuscore on 3/10.

Cronos Group:n ISIN on CA22717L1013. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Cronos Group:n WKN on A2DMQY. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Cronos Group:n ticker on CRON.TO. Tämä pörssinoteeraus käytetään Cronos Group-osakkeiden kauppaan pörssissä.

Cronos Group maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Cronos Group kuuluu sektoriin 'Terveydenhuolto'.

Cronos Group:n osingot jaetaan valuutassa USD.